DOCSLIB.ORG

US 2016/0076021 A1 Stojanovic Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 2016.0076021A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0076021 A1 Stojanovic et al. (43) Pub. Date: Mar. 17, 2016 (54) APTAMIER METHODS AND COMPOSITIONS (60) Provisional application No. 61/798,079, filed on Mar. 15, 2013. (71) Applicants: Milan N. Stojanovic, Fort Lee, NJ (US); Tilla S. Worgall, New York, NY (US); Kyung-Ae Yang, New York, NY (US) Publication Classification (51) Int. C. (72) Inventors: Milan N. Stojanovic, Fort Lee, NJ (US); CI2N 5/10 (2006.01) Tilla S. Worgall, New York, NY (US); GOIN33/53 (2006.01) Kyung-Ae Yang, New York, NY (US) CI2N 15/I 15 (2006.01) (73) Assignee: THE TRUSTEES OF COLUMBIA (52) U.S. C. UNIVERSITY IN THE CITY OF CPC .......... CI2N 15/1048 (2013.01); C12N 15/115 NEW YORK, NEW YORK, NY (US) (2013.01); G0IN33/5308 (2013.01); C12N 23 10/16 (2013.01); C12N 2320/13 (2013.01); (21) Appl. No.: 14/855,171 CI2N 2320/10 (2013.01) (22) Filed: Sep.15, 2015 (57) ABSTRACT Related U.S. Application Data Methods of selecting an aptamer that specifically binds to a (63) Continuation-in-part of application No. PCT/US14/ target molecule complexed with a derivatization agent. Also 29281, filed on Mar. 14, 2014. disclosed are specific aptamers and methods of use thereof. Patent Application Publication Mar. 17, 2016 Sheet 1 of 17 US 2016/0076021 A1 FIG. 1A - FIG. 1C A. receptor target receptor target B. w W, w s & 8 ww. ---O. “. 8:XXX Y targe Aptamer eaaceti organometallic receptors (metal, on eft, complexed to organic ligand, on right C. 8 *-*.s 8 k NY( ) 8 :g 8. 8: f G C & C YC. G1 3. A --- c.s d ( - || /> ciC A (s K d Ali d is C-C-GAG. A G-c G-d c.c.GAGA Gé & d; G-? N->->G G cT cT c-G d --G-G-c-f-c-f-c-de C- YPCR Amplification and Poo Regeneration V --- Patent Application Publication Mar. 17, 2016 Sheet 2 of 17 US 2016/0076021 A1 FIG. 1 D - FIG. 1E 1883$ CiA38isties asci roy: Stegesarakia. Patent Application Publication Mar. 17, 2016 Sheet 3 of 17 US 2016/0076021 A1 FIG. 2 -"olo s x8. Cp*R*AA Cp*RhAA isypii....- ... 3: ixitxii: :: *::::::ii Patent Application Publication Mar. 17, 2016 Sheet 4 of 17 US 2016/0076021 A1 FIG. 3A - FIG. 3F A. C. D. A. t-c -T c Sensor Sensitivity & A (tyrosine-Gprh sensor : 3 800 -1 NH -C *. 600 -g -t 40000 B. -- -é 200 --- - 8 500 1s -6 tyrosine conc. ut E. F. Sensor Selectivity (Tyrosine-CpRh sensor) 800 *000 x- Tyrosire re. Asis 80030 So exa. “*-. A-2-sites ArqiAt aga :: - - Cyster,C. 60000 40000: t 3ycits ise - Lysine 4000 26 -- Relhorite x 8 ------- --- Periyalarine 20038 8 tree- -s-- Metitionis:tryptophan ryosine healthy subject serum 0. 29 30 o 00 200 300 400 CpRh conc. (iv) a Dution times Patent Application Publication Mar. 17, 2016 Sheet 5 of 17 US 2016/0076021 A1 FIG. 4A - FIG. 4F A. B. C. NH C GC S is G T-c g-A cC-T A HN OH Ag a-G-G-A-d-G-G-A NH2 t cg A. Af G - C D. Sensor Sensitivity (Arginine-Cprh sensor) 100000 80000 s 6000 : 40000 20000 9 29 43 630 Arginine conc. (uN) E. F. Sensor Selectivity (Arginine-CpRh sensor) 0000 10000 r-8- Arginine r-- Cru: 80000 80000 -8-M-8 -- Garine -- Glycine o 60000 r0m. Hisine d 60000 l re- Methions:e : 2 - Ornithine 40000 40000 rar Tryptophar, 20000; -- tyrosipew 20000 0 3 2 40 80 O 100 200 360 400 CpRh conc. (uR) Dilution tinnes Patent Application Publication Mar. 17, 2016 Sheet 6 of 17 US 2016/0076021 A1 FIG. 4G - FIG. 4 G. H. *: it cofactor Kid 6 rv 3:N3:388x3:33 . J. 88: S388 88. 883 ic s : w 88: 23:38: 8 8 & 3& 8, 283 8 488 A88 8:38:::::::::3883 : &isio acid concertraict 388 Patent Application Publication Mar. 17, 2016 Sheet 7 of 17 US 2016/0076021 A1 FIG. 5A - FIG. 5F -8. 3. 88: & 83 3xxxxix. 888 &cs. 8:8 8. s& s: & Enex58 is 3. S. i.e. ii. Patent Application Publication Mar. 17, 2016 Sheet 8 of 17 US 2016/0076021 A1 FIG. 5G - FIG. 5N Sensor Selectivity Sensor Sensitivity (Giucose-oranic acid sensor) Glucose-Bororic acid sensor) 880 80s --------------. ---8 60000- *w8. Wax. ex 60s - f --&--. Gligosa -x^ s 8 -- iticss me - 400 rise toss : 40 -- Scaric acxd only aw (Saactoss --&-- 8sics & Succuse 200 2 000 X - - - 20 3. 4. so 2 49 s Sugar conc. (m) Boronic acid conc. (uM) - & 8 & s I. M-8 ---------------------------------------- s 8 4. s: & s Sixx xxx... x8 S&s six. 8 Patent Application Publication Mar. 17, 2016 Sheet 9 of 17 US 2016/0076021 A1 FIG. 6A - FIG. 6B 250 8. -* 2008 ^- *8* Glucose 15000 Y s8-: Goose ran Ficise . -- Ficose order Warfose '40000 g -- Aarose ---. Gaiacose --8e Gaciose 20 4. 6 O 5 53 surga conc. (m) Sugar conc. (ni) Patent Application Publication Mar. 17, 2016 Sheet 10 of 17 US 2016/0076021 A1 FIG. 7A - FIG. 7D x-Y. Tyr g Y. v A --- grrrrris ; : Corpex-bidingR -. r p motif1 on which& aptamer ---8 - 8. is built &- & Citruline C s'. Nor-Seitective e k Yx...' Cross-reactive - i rp SY.W --- : 8-- - 8 : : k a a. *k Patent Application Publication Mar. 17, 2016 Sheet 11 of 17 US 2016/0076021 A1 FIG. 7E - FIG. 7H --- 3 8 8 Patent Application Publication Mar. 17, 2016 Sheet 12 of 17 US 2016/0076021 A1 FIG. 8A - FIG. 8C sciective: Patent Application Publication Mar. 17, 2016 Sheet 13 of 17 US 2016/0076021 A1 FIG. 9A - FIG. 9C A B C g s A & & s & s & : AS: 3:38:::::8: $8388:w8 as ::::::&- . ; as 3. : Patent Application Publication Mar. 17, 2016 Sheet 14 of 17 US 2016/0076021 A1 FIG. 1 OA - FIG. 1 OB i.e. 8-8 8S 3. Sciectivey 3.fk Y---------g-r-g-g-a-S.--- -A- -s -4 overie 'N' W w i.e. Seisective ower is: & 8 : Y-------. Patent Application Publication Mar. 17, 2016 Sheet 15 of 17 US 2016/0076021 A1 FIG. 11A - FIG. 11B x PW Patent Application Publication Mar. 17, 2016 Sheet 16 of 17 US 2016/0076021 A1 FIG. 12A - FIG. 12B & &'s *... : A 60000 x Periyaarie rx tyrosie « tryptophare men glycine & XS.S.S.S.S.S.S.S.SYYYYY." o 1000 B Amino acid concentraton (u) Patent Application Publication Mar. 17, 2016 Sheet 17 of 17 US 2016/0076021 A1 FIG. 12C - FIG. 12D " e-o-o: 8. x. s -- Peya are or ryptopian -- tyrosite soo food * D Arrino acid concentration (iii) US 2016/0076021 A1 Mar. 17, 2016 APTAMER METHODS AND COMPOSITIONS isolating an eluted aptamer having high affinity for the target complex. In some embodiments, the method includes system CROSS-REFERENCE TO RELATED atic evolution of ligands by exponential enrichment APPLICATIONS (SELEX). 0001. The present application is a Continuation in Part of 0009. In some embodiments, the aptamer does not sub International Application No. PCT/US14/29281 filed 14 Mar. stantially bind the non-complexed target molecule. In some 2014, which claims the benefit of U.S. Provisional Applica embodiments, the aptamer does not substantially bind the tion Ser. No. 61/798,079 filed 15 Mar. 2013, each of which is non-complexed derivatization agent. In some embodiments, incorporated herein by reference in its entirety. the method includes counter-selecting an aptamer against the derivatization agent alone or against the target molecule STATEMENT REGARDING FEDERALLY alone. SPONSORED RESEARCH ORDEVELOPMENT 0010. In some embodiments, the oligonucleotide library includes randomly generated oligonucleotide sequences of a 0002 This invention was made with government support fixed length flanked by a constant 5' end and a constant 3' end, under grant numbers CBET-1033288 and CBET-1026592 the constant 5' end and the constant 3' end functioning as a awarded by National Science Foundation. The government primer. has certain rights in the invention. 0011. In some embodiments, the aptamer is a DNA, RNA, or XNA molecule. In some embodiments, the aptamer com MATERIAL INCORPORATED-BY-REFERENCE prises at least about 15 oligonucleotides up to about 100 0003. The Sequence Listing, which is a part of the present oligonucleotides. In some embodiments, the aptamer has an disclosure, includes a computer readable form comprising equilibrium constant (Kd) of about 1 pMup to about 10.0LM: nucleotide and/or amino acid sequences of the present inven about 1 pM up to about 1.0 uM; about 1 pMup to about 100 tion. The Subject matter of the Sequence Listing is incorpo nM; about 100 pM up to about 10.0 uM; about 100 pM up to rated herein by reference in its entirety. about 1.0 uM; about 100 pMup to about 100 nM; or about 1.0 nM up to about 10.0 uM; about 1.0 nM up to about 1.0 uM; BACKGROUND OF THE INVENTION about 1 nMup to about 200 nM; about 1.0 nMup to about 100 nM; about 500 nM up to about 10.0 uM; or about 500 nM up 0004 Systematic evolution of ligands by exponential to about 1.0 uM. enrichment (SELEX) is a combinatorial technique in molecu 0012. In some embodiments, the target molecule com lar biology for producing oligonucleotides of either single prises a small molecule, a protein, or a nucleic acid. In some stranded DNA or RNA that specifically bind to a target ligand embodiments, the target molecule comprises a small mol or ligands.
Recommended publications
  • Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis

    Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis

    Pediat. Res. 10: 683- 686 (1976) Fatty degeneration propionic acid hyperammonemia propionic acidemia liver ureagenesls Effect of Propionic Acid on Fatty Acid Oxidation and U reagenesis ALLEN M. GLASGOW(23) AND H. PET ER C HASE UniversilY of Colorado Medical Celller, B. F. SlOlillsky LaboralOries , Denver, Colorado, USA Extract phosphate-buffered salin e, harvested with a brief treatment wi th tryps in- EDTA, washed twice with ph os ph ate-buffered saline, and Propionic acid significantly inhibited "CO z production from then suspended in ph os ph ate-buffe red saline (145 m M N a, 4.15 [I-"ejpalmitate at a concentration of 10 11 M in control fibroblasts m M K, 140 m M c/, 9.36 m M PO" pH 7.4) . I n mos t cases the cells and 100 11M in methyl malonic fibroblasts. This inhibition was we re incubated in 3 ml phosph ate-bu ffered sa lin e cont aining 0.5 similar to that produced by 4-pentenoic acid. Methylmalonic acid I1Ci ll-I4Cj palm it ate (19), final concentration approximately 3 11M also inhibited ' 'C0 2 production from [V 'ejpalmitate, but only at a added in 10 II I hexane. Increasing the amount of hexane to 100 II I concentration of I mM in control cells and 5 mM in methyl malonic did not impair palmit ate ox id ation. In two experiments (Fig. 3) the cells. fibroblasts were in cub ated in 3 ml calcium-free Krebs-Ringer Propionic acid (5 mM) also inhibited ureagenesis in rat liver phosphate buffer (2) co nt ain in g 5 g/ 100 ml essent iall y fatty ac id slices when ammonia was the substrate but not with aspartate and free bovine se rum albumin (20), I mM pa lm itate, and the same citrulline as substrates.
  • Inherited Metabolic Disease

    Inherited Metabolic Disease

    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
  • Involvements of Hyperhomocysteinemia in Neurological Disorders

    Involvements of Hyperhomocysteinemia in Neurological Disorders

    H OH metabolites OH Review Involvements of Hyperhomocysteinemia in Neurological Disorders Marika Cordaro 1,† , Rosalba Siracusa 2,† , Roberta Fusco 2 , Salvatore Cuzzocrea 2,3,* , Rosanna Di Paola 2,* and Daniela Impellizzeri 2 1 Department of Biomedical, Dental and Morphological and Functional Imaging, University of Messina, Via Consolare Valeria, 98125 Messina, Italy; [email protected] 2 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy; [email protected] (R.S.); [email protected] (R.F.); [email protected] (D.I.) 3 Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA * Correspondence: [email protected] (S.C.); [email protected] (R.D.P.); Tel.: +39-090-6765208 (S.C. & R.D.P.) † The authors equally contributed to the review. Abstract: Homocysteine (HCY), a physiological amino acid formed when proteins break down, leads to a pathological condition called hyperhomocysteinemia (HHCY), when it is over a definite limit. It is well known that an increase in HCY levels in blood, can contribute to arterial damage and several cardiovascular disease, but the knowledge about the relationship between HCY and brain disorders is very poor. Recent studies demonstrated that an alteration in HCY metabolism or a deficiency in folate or vitamin B12 can cause altered methylation and/or redox potentials, that leads to a modification on calcium influx in cells, or into an accumulation in amyloid and/or tau protein involving a cascade of events that culminate in apoptosis, and, in the worst conditions, neuronal death. The present review will thus summarize how much is known about the possible role of HHCY in neurodegenerative disease.
  • Metabolomic Analysis Reveals That the Drosophila Gene Lysine Influences Diverse Aspects of Metabolism

    Metabolomic Analysis Reveals That the Drosophila Gene Lysine Influences Diverse Aspects of Metabolism

    Genetics: Early Online, published on October 6, 2017 as 10.1534/genetics.117.300201 Metabolomic analysis reveals that the Drosophila gene lysine influences diverse aspects of metabolism Samantha L. St. Clair*‡, Hongde Li*‡, Usman Ashraf†, Jonathan A. Karty†, and Jason M. *§ Tennessen * Department of Biology, Indiana University, Bloomington, IN 47405, USA † Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA. ‡ These authors contributed equally to this work. § Correspondence: [email protected] Keywords: Drosophila, metabolomics, lysine, LKRSDH, familial hyperlysinemia 1 Copyright 2017. ABSTRACT The fruit fly Drosophila melanogaster has emerged as a powerful model for investigating the molecular mechanisms that regulate animal metabolism. A major limitation of these studies, however, is that many metabolic assays are tedious, dedicated to analyzing a single molecule, and rely on indirect measurements. As a result, Drosophila geneticists commonly use candidate gene approaches, which, while important, bias studies towards known metabolic regulators. In an effort to expand the scope of Drosophila metabolic studies, we used the classic mutant lysine (lys) to demonstrate how a modern metabolomics approach can be used to conduct forward genetic studies. Using an inexpensive and well-established gas chromatography-mass spectrometry (GC-MS)-based method, we genetically mapped and molecularly characterized lys by using free lysine levels as a phenotypic readout. Our efforts revealed that lys encodes the Drosophila homolog of Lysine Ketoglutarate Reductase/Saccharopine Dehydrogenase (LKRSDH), which is required for the enzymatic degradation of lysine. Furthermore, this approach also allowed us to simultaneously survey a large swath of intermediate metabolism, thus demonstrating that Drosophila lysine catabolism is complex and capable of influencing seemingly unrelated metabolic pathways.
  • Amino Acid Disorders

    Amino Acid Disorders

    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
  • Formula Name Category Description Qualifying

    Formula Name Category Description Qualifying

    Memorandum #17-079 TO: WIC Regional Directors WIC Local Agency Directors FROM: Amanda Hovis, Director Nutrition Education/Clinic Services Unit Nutrition Services Section DATE: August 4, 2017 SUBJECT: Revised Formula Approval Resources Posted The formula approval resources have been revised to reflect the recent clinic formula table changes and will be posted to the DSHS WIC website. You will be able view them at the following link under “Formula Approval Resources” once they are posted. http://www.dshs.texas.gov/wichd/nut/foods-nut.shtm The following documents have been revised for July, 2017. Presently, they are attached to this memo as PDF files. 1. Texas WIC Formulary 2. Formula Code List 3. Texas WIC Formula Maximum Quantity Table 4. Nutrition Assessment Requirements Guide If you have questions or require additional information, contact Pat Koym, Formula Specialist, at [email protected] or 512-341-4578. This institution is an equal opportunity provider TEXAS WIC FORMULARY AND MEDICAL REASONS FOR ISSUANCE JULY 2017 Formula Category Description Qualifying Conditions Staff Instructions - May issue for 1 cert Manufacturer Name period unless otherwise indicated Alfamino Infant Elemental 20 cal/oz when mixed 1 scoop to 1 oz 1) Malabsorption syndrome Formula history required. Nestle water; hypoallergenic amino acid 2) GI impairment When requested for food allergy - a failed trial of a protein based elemental. 43% of fat is MCT 3) GER/GERD hydrolysate (Extensive HA, Nutramigen, Alimentum, or oil; Similar to Elecare DHA/ARA, 4) Food allergies (cow's milk, soy or Pregestimil) is recommended before issuing unless medically Neocate DHA/ARA and PurAmino.
  • Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters

    Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters

    European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y.
  • Congenital Ocular Anomalies in Newborns: a Practical Atlas

    Congenital Ocular Anomalies in Newborns: a Practical Atlas

    www.jpnim.com Open Access eISSN: 2281-0692 Journal of Pediatric and Neonatal Individualized Medicine 2020;9(2):e090207 doi: 10.7363/090207 Received: 2019 Jul 19; revised: 2019 Jul 23; accepted: 2019 Jul 24; published online: 2020 Sept 04 Mini Atlas Congenital ocular anomalies in newborns: a practical atlas Federico Mecarini1, Vassilios Fanos1,2, Giangiorgio Crisponi1 1Neonatal Intensive Care Unit, Azienda Ospedaliero-Universitaria Cagliari, University of Cagliari, Cagliari, Italy 2Department of Surgery, University of Cagliari, Cagliari, Italy Abstract All newborns should be examined for ocular structural abnormalities, an essential part of the newborn assessment. Early detection of congenital ocular disorders is important to begin appropriate medical or surgical therapy and to prevent visual problems and blindness, which could deeply affect a child’s life. The present review aims to describe the main congenital ocular anomalies in newborns and provide images in order to help the physician in current clinical practice. Keywords Congenital ocular anomalies, newborn, anophthalmia, microphthalmia, aniridia, iris coloboma, glaucoma, blepharoptosis, epibulbar dermoids, eyelid haemangioma, hypertelorism, hypotelorism, ankyloblepharon filiforme adnatum, dacryocystitis, dacryostenosis, blepharophimosis, chemosis, blue sclera, corneal opacity. Corresponding author Federico Mecarini, MD, Neonatal Intensive Care Unit, Azienda Ospedaliero-Universitaria Cagliari, University of Cagliari, Cagliari, Italy; tel.: (+39) 3298343193; e-mail: [email protected].
  • Analysis of Body Composition and Nutritional Status in Brazilian Phenylketonuria Patients

    Analysis of Body Composition and Nutritional Status in Brazilian Phenylketonuria Patients

    Molecular Genetics and Metabolism Reports 6 (2016) 16–20 Contents lists available at ScienceDirect Molecular Genetics and Metabolism Reports journal homepage: www.elsevier.com/locate/ymgmr Analysis of body composition and nutritional status in Brazilian phenylketonuria patients Priscila Nicolao Mazzola a,b, Tatiele Nalin c,⁎, Kamila Castro d,MargreetvanRijnb, Terry G.J. Derks b, Ingrid D.S. Perry e, Alberto Scofano Mainieri f, Ida Vanessa D. Schwartz c,g,h a Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2600 anexo, 90035-003, Porto Alegre, Brazil b Beatrix Children's Hospital, Section of Metabolic Diseases, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands c Post-Graduation Program in Genetics and Molecular Biology, UFRGS, Bento Gonçalves 9500/43323M, PO Box 15053, Porto Alegre, Brazil d Postgraduate Program in Pediatrics and Adolescent Health, UFRGS, Ramiro Barcelos 2400, 90035-003, Porto Alegre, Brazil e Postgraduate Program in Collective Health, Health Unit, Universidade do Extremo Sul Catarinense, Universitária 1105, 88806-000 Criciúma, Brazil f Department of Pediatrics, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2400, 90035-003 Porto Alegre, Brazil g Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, Brazil h Department of Genetics, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, Brazil article info abstract Article history: Background: Phenylketonuria (PKU) is characterized by phenylalanine (Phe) accumulation to toxic levels due to Received 20 November 2015 the low activity of phenylalanine-hydroxylase.
  • MILD HYPERHOMOCYSTEINEMIA and ARTERIAL OCCLUSIVE DISEASE JACOB SELHUB USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

    MILD HYPERHOMOCYSTEINEMIA and ARTERIAL OCCLUSIVE DISEASE JACOB SELHUB USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

    Journal of Hematology volume 82 – number 2 – March-April 1997 editorial MILD HYPERHOMOCYSTEINEMIA AND ARTERIAL OCCLUSIVE DISEASE JACOB SELHUB USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA he initial link between homocysteine and vas- ic vascular disease, with odds ratios for a 5 umol/L cular disease was made by McCully approxi- increase in plasma tHcy that were equal to 1.5-1.8 Tmately 25 years ago.1 He observed that an for men and women with CHD, cerebrovascular or infant who died as a result of a rare genetic condi- peripheral vascular diseases. tion of abnormal cobalamin metabolism with Our interest in homocysteine was prompted by homocystinuria exhibited widespread, severe arte- the possibility that plasma homocysteine may serve riosclerosis analogous to the lesions seen in cases of as an indicator of the status and perhaps the intake homocystinuria caused by a genetic cystathionine of a number of vitamins, including folic acid, vita- ␤-synthase deficiency. Because hyperhomocysteine- min B12 and vitamin B6. This possibility derived mia was the only condition common to these two from the large number of studies which implied metabolic disorders, McCully proposed that hyper- that methionine metabolism is tightly regulated,3,6,7 homocysteinemia resulted in arteriosclerotic dis- and from other studies which showed that deficien- ease. Although McCully’s hypothesis did not gain cies in the above vitamins are often associated with immediate support, the association between plas- hyperhomocysteinemia.8-18 ma homocysteine concentration and arteriosclero- The aims of our studies were therefore: 1) to sis has more recently become the subject of a num- determine the relationship between plasma homo- ber of clinical studies.
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al

    US 20160281 166A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE et al. (43) Pub. Date: Sep. 29, 2016 (54) METHODS AND SYSTEMIS FOR SCREENING Publication Classification DISEASES IN SUBJECTS (51) Int. Cl. (71) Applicant: PARABASE GENOMICS, INC., CI2O I/68 (2006.01) Boston, MA (US) C40B 30/02 (2006.01) (72) Inventors: Arindam BHATTACHARJEE, G06F 9/22 (2006.01) Andover, MA (US); Tanya (52) U.S. Cl. SOKOLSKY, Cambridge, MA (US); CPC ............. CI2O 1/6883 (2013.01); G06F 19/22 Edwin NAYLOR, Mt. Pleasant, SC (2013.01); C40B 30/02 (2013.01); C12O (US); Richard B. PARAD, Newton, 2600/156 (2013.01); C12O 2600/158 MA (US); Evan MAUCELI, (2013.01) Roslindale, MA (US) (21) Appl. No.: 15/078,579 (57) ABSTRACT (22) Filed: Mar. 23, 2016 Related U.S. Application Data The present disclosure provides systems, devices, and meth (60) Provisional application No. 62/136,836, filed on Mar. ods for a fast-turnaround, minimally invasive, and/or cost 23, 2015, provisional application No. 62/137,745, effective assay for Screening diseases, such as genetic dis filed on Mar. 24, 2015. orders and/or pathogens, in Subjects. Patent Application Publication Sep. 29, 2016 Sheet 1 of 23 US 2016/0281166 A1 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS S{}}\\93? sau36 Patent Application Publication Sep. 29, 2016 Sheet 2 of 23 US 2016/0281166 A1 &**** ? ???zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz??º & %&&zzzzzzzzzzzzzzzzzzzzzzz &Sssssssssssssssssssssssssssssssssssssssssssssssssssssssss & s s sS ------------------------------ Patent Application Publication Sep. 29, 2016 Sheet 3 of 23 US 2016/0281166 A1 23 25 20 FG, 2. Patent Application Publication Sep. 29, 2016 Sheet 4 of 23 US 2016/0281166 A1 : S Patent Application Publication Sep.
  • Table S1. Disease Classification and Disease-Reaction Association

    Table S1. Disease Classification and Disease-Reaction Association

    Table S1. Disease classification and disease-reaction association Disorder class Associated reactions cross Disease Ref[Goh check et al.